


# Stabilis



## Nicardipine hydrochloride



### Stabilité des préparations


		100 mg	Eau ppi 3,5 mL Polysorbate 80 0,5 g Inorpha® >> 50 mL	15-25°C		90		4563
		100 mg	Eau ppi 3,5 mL Polysorbate 80 0,5 g Inorpha® >> 50 mL	2-8°C		90		4563




### Bibliographie

	Type	Source
4563	Revue	Fuss D, Gondé H, Lamoureux F, Pereira T, Colnot M, Buchbinder N, Coquard A, Varin R, Hervouët C. Stability study of a compounded oral solution of nicardipine for the treatment of hypertension in children. Eur J Pharm Sci 2021 ; 160: 105738.

# Stabilis



## Nicardipine hydrochloride



Noms commerciaux

Cardene	Etats Unis d'Amérique, Pays bas
Cardepine	Malaisie
Loxen	France, Maroc, Tunisie
Nicardipine	Belgique, Etats Unis d'Amérique, Grande Bretagne, Roumanie
Perdipine	Japon
Rycarden	Suède
Rydene	Belgique, Luxembourg
Vasonase	Espagne



### Stabilité des solutions

		0,05 & 0,5 mg/ml	18°C-28°C		7			44
		0,1 mg/ml	25°C		24			3614
		0,1 mg/ml	25°C		24			3614
	<b>RL</b>	0,05 & 0,5 mg/ml	18°C-28°C		7			44
		0,1 mg/ml	25°C		24			3614
		0,1 mg/ml	25°C		24			3614
		0,1 mg/ml	25°C		24			3614
		0,1 mg/ml	25°C		24			3614
		0,1-0,2 mg/ml	25°C		24			3941


































































### Facteur influençant la stabilité

	<b>RL</b>			3614
	<b>NaH CO3</b>			3941
	<b>NaH CO3</b>			44 3614
	<b>PVC</b>			44
	<b>PH &gt; 6</b>			3941



## Compatibilités

				
		Nicardipine hydrochloride		3614
		Nicardipine hydrochloride : 0,2 mg/ml		4603
		Nicardipine hydrochloride : 0.1 mg/ml Amikacin sulfate : 2 mg/ml		1490
		Nicardipine hydrochloride		3614
		Nicardipine hydrochloride : 0.1 mg/ml Aminophylline : 1 mg/ml		1490
		Nicardipine hydrochloride : 0.05 & 0.5 mg/ml		44
		Nicardipine hydrochloride : 1 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Nicardipine hydrochloride : 0.1 mg/ml Ampicillin sodium : 10 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Ampicillin sodium - sulbactam sodium : 15 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Aztreonam : 10 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Butorphanol tartrate : 0.4 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Calcium gluconate : 19.8 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Nicardipine hydrochloride : 0.1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Nicardipine hydrochloride : 0.1 mg/ml Cefoperazone sodium : 10 mg/ml		1490
		Nicardipine hydrochloride		3941
		Nicardipine hydrochloride : 0.1 mg/ml Cefazolin sodium : 20 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Ceftazidime : 10 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Ceftazidime : 125 mg/ml		2141
		Nicardipine hydrochloride : 1 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Nicardipine hydrochloride : 0.1 mg/ml Ceftizoxime sodium : 10 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Nicardipine hydrochloride : 0.1 mg/ml Chloramphenicol sodium succinate : 10 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Cimetidine hydrochloride : 3 mg/ml		1490
		Nicardipine hydrochloride : 0,5 mg/ml Cisatracurium besylate : 1 mg/ml		3429

	Nicardipine hydrochloride : 0.1 mg/ml Clindamycin phosphate : 9 mg/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Co-trimoxazole : 0.8/1.6 mg/ml		1490
	Nicardipine hydrochloride : 0.5 mg/ml Defibrotide : 8 mg/ml		3728
	Nicardipine hydrochloride Diazepam		3614
	Nicardipine hydrochloride Diazepam		3941
	Nicardipine hydrochloride : 1 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
	Nicardipine hydrochloride : 0.1 mg/ml Dobutamine hydrochloride : 1 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
	Nicardipine hydrochloride : 0.1 mg/ml Dopamine hydrochloride : 1.6 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Nicardipine hydrochloride : 0.1 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Nicardipine hydrochloride : 0.1 mg/ml Enalaprilate : 0.5 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Nicardipine hydrochloride : 0,1 mg/ml Eravacycline : 0,6 mg/ml		4434
	Nicardipine hydrochloride : 0.1 mg/ml Erythromycin lactobionate : 5 mg/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Esmolol hydrochloride : 10 mg/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Famotidine : 0.2 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Nicardipine hydrochloride : 1 mg/ml Fentanyl citrate : 50 µg/ml		314
	Nicardipine hydrochloride : 0.1 mg/ml Fentanyl citrate : 2 µg/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Fosfomycin : 30 mg/ml		4055
	Nicardipine hydrochloride : 1 mg/ml Furosemide : 10 mg/ml		314
	Nicardipine hydrochloride Furosemide		3614
	Nicardipine hydrochloride Furosemide		3941
	Nicardipine hydrochloride : 0.1 mg/ml Gentamicin sulfate : 0.8 mg/ml		1490
	Nicardipine hydrochloride Heparin sodium		3540

		Nicardipine hydrochloride : 0.1 mg/ml Heparin sodium : 40 UI/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Heparin sodium : 100 UI/ml		314
		Nicardipine hydrochloride : 0.1 mg/ml Hetastarch : 60 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Hydrocortisone sodium succinate : 2 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Nicardipine hydrochloride : 0.2 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Nicardipine hydrochloride : 0,2 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
		Nicardipine hydrochloride : 1 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Nicardipine hydrochloride : 0.1 mg/ml Labetalol hydrochloride : 1 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Nicardipine hydrochloride : 0.1 mg/ml Lidocaine hydrochloride : 4 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Linezolid : 2 mg/ml		1925
		Nicardipine hydrochloride : 1 mg/ml Lorazepam : 0.5 mg/ml		314
		Nicardipine hydrochloride : 0.1 mg/ml Magnesium sulfate : 600 mg/ml		1490
		Nicardipine hydrochloride Methohexital sodium		3614
		Nicardipine hydrochloride Methohexital sodium		3941
		Nicardipine hydrochloride : 0.1 mg/ml Methylprednisolone sodium succinate : 0.8 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Metronidazole : 5 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Micafungin : 1.5 mg/ml		2108
		Nicardipine hydrochloride : 1 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Nicardipine hydrochloride : 0,4 mg/ml Milrinone lactate : 1 mg/ml		4506
		Nicardipine hydrochloride : 1 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Nicardipine hydrochloride : 1 mg/ml Morphine sulfate : 2 mg/ml		314
		Nicardipine hydrochloride : 0.1 mg/ml Morphine sulfate : 0.2 mg/ml		1490
		Nicardipine hydrochloride : 0.1 mg/ml Nafcillin sodium : 10 mg/ml		1490
		Nicardipine hydrochloride : 1 mg/ml Nefopam : 0,16 mg/ml		4698

	Nicardipine hydrochloride : 1 mg/ml Nitroglycerin : 0.4 mg/ml		314
	Nicardipine hydrochloride : 0.1 mg/ml Nitroprusside sodium : 0.2 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	Nicardipine hydrochloride : 1 mg/ml Paracetamol : 10 mg/ml		4742
	Nicardipine hydrochloride : 0.1 mg/ml Penicillin G potassium : 0.05 MUI/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Piperacillin sodium : 12 mg/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Nicardipine hydrochloride : 0.05 & 0.5 mg/ml Potassium chloride : 40 mEq/l		44
	Nicardipine hydrochloride : 0.1 mg/ml Potassium chloride : 400 mEq/l		1490
	Nicardipine hydrochloride : 0.1 mg/ml Potassium phosphate : 0.44 mmol/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
	Nicardipine hydrochloride Sodium bicarbonate		3614
	Nicardipine hydrochloride : 0,05 & 0,5 mg/ml Sodium bicarbonate : 50 mg/ml		44
	Nicardipine hydrochloride Sodium bicarbonate		3941
	Nicardipine hydrochloride : 0,1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Nicardipine hydrochloride : 0.2 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Nicardipine hydrochloride : 1 mg/ml Temocilline : 83.33 mg/ml		2231
	Nicardipine hydrochloride Temocilline		4470
	Nicardipine hydrochloride : 1 mg/ml Thiopental sodium : 25 mg/ml		314
	Nicardipine hydrochloride Thiopental sodium		3941
	Nicardipine hydrochloride Thiopental sodium		3614
	Nicardipine hydrochloride : 0.1 mg/ml Tobramycin sulfate : 0.8 mg/ml		1490
	Nicardipine hydrochloride : 0.1 mg/ml Vancomycin hydrochloride : 5 mg/ml		1490
	Nicardipine hydrochloride : 1 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	Nicardipine hydrochloride : 1 mg/ml Vecuronium bromide : 1 mg/ml		314



**Bibliographie**

	Type	Source
44	Revue	Baaske DM, DeMay JF, Latona CA, Mirmira S, Sigvardson KW. Stability of nicardipine hydrochloride in intravenous solutions. Am J Health-Syst Pharm 1996 ; 53: 1701-1705.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1759	Revue	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaisn with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.



3429	Revue	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3614	Laboratoire	Nicardipine Injection - Summary of Product Characteristics American Regent Inc 2013
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3941	Laboratoire	Nicardipine - Summary of Product Characteristics Concordia International 2017
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4470	Revue	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4506	Revue	Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.



4698	Revue	Ayari G, D&#39;Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



# Dictionnaire

 Antihypertenseur	 Solution buvable
 Stabilité des préparations	 Contenant
 Origine	 Excipient
 Température	 Conservation
 Durée de stabilité	 Biosimilaire
 Données conflictuelles	 Bibliographie
 Verre	 Poudre
 A l'abri de la lumière	 Jour
 Bibliographie	 Vasodilatateur
 Injectable	 Noms commerciaux
 Stabilité des solutions	 Molécule
 Concentration	 NaCl 0,9% ou glucose 5%
 Lumière	 Chlorure de sodium 0,9%
 Heure	 Glucose 5%
<b>RL</b> Ringer lactate	 Chlorure de sodium 0,45%
 Polyvinyl chlorure	 Seringue polypropylène
 Facteur influençant la stabilité	 Solvant
 Provoque	 Dégradation
 NaHCO <sub>3</sub>	 Précipitation
 Adsorption	 Compatibilités
 Molécule	 Précipitation immédiate
 Incompatible	 Compatible
 Changement de couleur	 Turbidité immédiate
 Eau pour préparation injectable	 Précipitation en 4 heures
 Précipitation en 1 heure	 Incompatibilité non précisée
 Aucun	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse
 Dictionnaire	